Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2007 3
2008 4
2009 4
2010 7
2011 7
2012 7
2013 9
2014 8
2015 8
2016 10
2017 13
2018 13
2019 5
2020 7
2021 4
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

91 results
Results by year
Filters applied: . Clear all
Page 1
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial.
Horwitz S, O'Connor OA, Pro B, Illidge T, Fanale M, Advani R, Bartlett NL, Christensen JH, Morschhauser F, Domingo-Domenech E, Rossi G, Kim WS, Feldman T, Lennard A, Belada D, Illés Á, Tobinai K, Tsukasaki K, Yeh SP, Shustov A, Hüttmann A, Savage KJ, Yuen S, Iyer S, Zinzani PL, Hua Z, Little M, Rao S, Woolery J, Manley T, Trümper L; ECHELON-2 Study Group. Horwitz S, et al. Lancet. 2019 Jan 19;393(10168):229-240. doi: 10.1016/S0140-6736(18)32984-2. Epub 2018 Dec 4. Lancet. 2019. PMID: 30522922 Free PMC article. Clinical Trial.
Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial.
Poeschel V, Held G, Ziepert M, Witzens-Harig M, Holte H, Thurner L, Borchmann P, Viardot A, Soekler M, Keller U, Schmidt C, Truemper L, Mahlberg R, Marks R, Hoeffkes HG, Metzner B, Dierlamm J, Frickhofen N, Haenel M, Neubauer A, Kneba M, Merli F, Tucci A, de Nully Brown P, Federico M, Lengfelder E, di Rocco A, Trappe R, Rosenwald A, Berdel C, Maisenhoelder M, Shpilberg O, Amam J, Christofyllakis K, Hartmann F, Murawski N, Stilgenbauer S, Nickelsen M, Wulf G, Glass B, Schmitz N, Altmann B, Loeffler M, Pfreundschuh M; FLYER Trial Investigators; German Lymphoma Alliance. Poeschel V, et al. Among authors: witzens harig m. Lancet. 2019 Dec 21;394(10216):2271-2281. doi: 10.1016/S0140-6736(19)33008-9. Lancet. 2019. PMID: 31868632 Clinical Trial.
NKT cells - New players in CAR cell immunotherapy?
Kriegsmann K, Kriegsmann M, von Bergwelt-Baildon M, Cremer M, Witzens-Harig M. Kriegsmann K, et al. Among authors: witzens harig m. Eur J Haematol. 2018 Dec;101(6):750-757. doi: 10.1111/ejh.13170. Epub 2018 Oct 9. Eur J Haematol. 2018. PMID: 30187578 Review.
Ibrutinib.
Charalambous A, Schwarzbich MA, Witzens-Harig M. Charalambous A, et al. Among authors: witzens harig m. Recent Results Cancer Res. 2018;212:133-168. doi: 10.1007/978-3-319-91439-8_7. Recent Results Cancer Res. 2018. PMID: 30069629
Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study.
Dreyling M, Jurczak W, Jerkeman M, Silva RS, Rusconi C, Trneny M, Offner F, Caballero D, Joao C, Witzens-Harig M, Hess G, Bence-Bruckler I, Cho SG, Bothos J, Goldberg JD, Enny C, Traina S, Balasubramanian S, Bandyopadhyay N, Sun S, Vermeulen J, Rizo A, Rule S. Dreyling M, et al. Among authors: witzens harig m. Lancet. 2016 Feb 20;387(10020):770-8. doi: 10.1016/S0140-6736(15)00667-4. Epub 2015 Dec 7. Lancet. 2016. PMID: 26673811 Clinical Trial.
Cellular Immunotherapy in B-Cell Malignancy.
Schwarzbich MA, Witzens-Harig M. Schwarzbich MA, et al. Among authors: witzens harig m. Oncol Res Treat. 2017;40(11):674-681. doi: 10.1159/000481946. Epub 2017 Oct 20. Oncol Res Treat. 2017. PMID: 29065420 Review.
Rituximab maintenance for the treatment of patients with follicular lymphoma: an updated systematic review and meta-analysis of randomized trials.
Vidal L, Gafter-Gvili A, Salles G, Dreyling MH, Ghielmini M, Hsu Schmitz SF, Pettengell R, Witzens-Harig M, Shpilberg O. Vidal L, et al. Among authors: witzens harig m. J Natl Cancer Inst. 2011 Dec 7;103(23):1799-806. doi: 10.1093/jnci/djr418. Epub 2011 Oct 21. J Natl Cancer Inst. 2011. PMID: 22021664 Review.
CAMK1D Triggers Immune Resistance of Human Tumor Cells Refractory to Anti-PD-L1 Treatment.
Volpin V, Michels T, Sorrentino A, Menevse AN, Knoll G, Ditz M, Milenkovic VM, Chen CY, Rathinasamy A, Griewank K, Boutros M, Haferkamp S, Berneburg M, Wetzel CH, Seckinger A, Hose D, Goldschmidt H, Ehrenschwender M, Witzens-Harig M, Szoor A, Vereb G, Khandelwal N, Beckhove P. Volpin V, et al. Among authors: witzens harig m. Cancer Immunol Res. 2020 Sep;8(9):1163-1179. doi: 10.1158/2326-6066.CIR-19-0608. Epub 2020 Jul 14. Cancer Immunol Res. 2020. PMID: 32665263 Free article.
91 results